ClinicalTrials.gg
RecruitingNCT07351474Updated Nov 4, 2026

Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy

An interventional study of Remimazolam and Propofol in Gastric Cancer and Postoperative Delirium, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 65 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 4, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
65 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University — 21 open to participants now, 24 under way, 2 of them phase 3. Stomach Neoplasms · The First Affiliated Hospital with Nanjing Medical University.

Planned enrollment
5th of 23
170 · median 50
Started
2026
with 6 others
No phase
5 of 28
4 open now
Primary completion
2026-12
later than 10 of 23 live
Registered
24th of 28
by date

Among the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2026, is one of 5 with no phase, reaches primary completion later than 10 of the 23 other live ones, and was the 24th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

21 of the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 65 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University, or all of them as a file.
02

Study summary

This prospective, single-center, randomized, participant- and outcome assessor-blinded, parallel-group controlled trial evaluated whether remimazolam-based anesthesia reduced postoperative delirium (POD) and improved peri-induction hemodynamic stability compared with propofol-midazolam-based anesthesia in patients aged 65 years or older undergoing elective laparoscopic radical gastrectomy for gastric cancer. A total of 147 participants were randomized in a 1:1 ratio. Standardized perioperative management, BIS-guided anesthetic depth control, and postoperative analgesia were applied in both groups. The primary outcome was the cumulative incidence of POD during postoperative days 1-3, assessed once daily using the 3D-CAM or CAM-ICU by trained outcome assessors blinded to treatment allocation. Secondary outcomes included post-induction hypotension, peri-induction hemodynamic variables, postoperative recovery, pain scores, and adverse events.

Read the detailed description

This prospective, single-center, randomized, participant- and outcome assessor-blinded, parallel-group controlled trial was conducted at the First Affiliated Hospital of Nanjing Medical University between January 21 and August 5, 2026. Patients aged 65 years or older who were scheduled to undergo elective laparoscopic radical gastrectomy for gastric cancer were screened for eligibility. A total of 147 participants were randomized in a 1:1 ratio to receive either remimazolam-based anesthesia or propofol-midazolam-based anesthesia. Randomization was based on a computer-generated sequence, with allocation concealed using sequentially numbered, opaque, sealed envelopes. Participants and postoperative outcome assessors were blinded to treatment allocation, whereas the attending anesthesiologists administering the allocated anesthetic regimen were not blinded.

Standardized perioperative monitoring and management were applied in both groups, including bispectral index-guided anesthetic depth control, opioid analgesia, neuromuscular blockade, controlled ventilation, vasoactive medication titration, and postoperative patient-controlled intravenous analgesia. Postoperative delirium was assessed once daily between 14:00 and 17:00 on postoperative days 1-3. Ward patients were assessed using the 3-Minute Diagnostic Interview for Confusion Assessment Method, whereas patients admitted to the intensive care unit were assessed using the Confusion Assessment Method for the Intensive Care Unit.

The original protocol specified standardized delirium assessment through postoperative day 5. Owing to limited research personnel during trial implementation, standardized assessments could only be consistently completed through postoperative day 3. Therefore, the primary outcome was the cumulative incidence of POD during postoperative days 1-3, and no assumptions were made regarding delirium status on postoperative days 4 and 5. Secondary outcomes included post-induction hypotension, maximum reduction in mean arterial pressure from baseline, peri-induction vasoactive drug requirements, peri-induction mean arterial pressure, heart rate and bispectral index trajectories, time to extubation, length of stay in the post-anesthesia care unit and hospital, postoperative pain scores, postoperative nausea and vomiting, PACU hypoxemia, emergence agitation, unplanned intensive care unit admission, and postoperative pulmonary infection.

03

Conditions studied

  • Gastric Cancer
  • Postoperative Delirium

Keywords

  • Remimazolam
  • Propofol
  • Elderly Patients
  • Laparoscopic Gastrectomy
  • Anesthesia
  • Postoperative Delirium
04

Who can participate

Ages eligible
65 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 65 years.
  • (BMI) between 18 and 28 kg/m².
  • I-III.
  • Scheduled for elective laparoscopic radical gastrectomy under general anesthesia at Jiangsu Province Hospital.
  • Able and willing to sign .

Exclusion criteria

Exclusion Criteria:

  • Severe respiratory, cardiovascular, renal, or hepatic dysfunction.
  • Stroke within the past 6 months or other central nervous system diseases.
  • History of schizophrenia, epilepsy, Parkinson's disease, myasthenia gravis, or other psychiatric disorders.
  • History of alcohol abuse or psychoactive substance dependence.
  • Severe visual, hearing, or language impairment preventing communication.
  • Allergy or to propofol or benzodiazepines.
  • Preoperative cognitive impairment assessed by (≤24 for ≥middle-school education; ≤20 for primary school; ≤17 for no formal education).
  • Participation in another drug clinical trial within 1 month before surgery.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Remimazolam Group

    Participants in this group will receive remimazolam for anesthesia induction and maintenance during laparoscopic radical gastrectomy.

    Drug: Remimazolam

  • Active comparator
    Propofol Group

    Participants in this group will receive propofol for anesthesia induction and maintenance during laparoscopic radical gastrectomy.

    Drug: Propofol

Interventions

  • Remimazolam will be used as the primary anesthetic agent for induction and maintenance. Dosage will be adjusted to maintain BIS between 40 and 60.

  • Propofol will be used as the primary anesthetic agent for induction and maintenance. Dosage will be adjusted to maintain BIS between 40 and 60.

06

What researchers measure

Primary outcomes

  1. incidence of Postoperative Delirium

    Postoperative delirium will be assessed using the 3D-CAM diagnostic tool by trained evaluators blinded to group assignment. Delirium will be identified based on the presence of acute onset/fluctuation, inattention, altered consciousness, or disorganized thinking, following the standard 3D-CAM algorithm.

    Time frame: From postoperative Day 1 to Day 3

Secondary outcomes

  1. Emergence Agitation

    Emergence agitation will be assessed in the PACU using the RASS or agitation scale by blinded evaluators.

    Time frame: Immediately after extubation until PACU discharge

  2. Time to extubation

    Time from discontinuation of anesthetic agents to successful tracheal extubation.

    Time frame: At the end of surgery

  3. Postoperative Pain Score

    Pain itensity will be evaluated using the Numerical Rating Scale(NRS,0-10)

    Time frame: At PACU discharge; postoperative day 1,day 2,and day 3.

  4. Post-induction Hypotension

    Post-induction hypotension will be defined as a decrease in mean arterial pressure (MAP) to \<65 mmHg or a reduction of ≥30% from baseline within the first 10 minutes after anesthetic induction.

    Time frame: From completion of anesthetic induction to 10 minutes after induction.

  5. Incidence of Postoperative Nausea and Vomiting

    Postoperative nausea and vomiting assessed as the presence or absence based on patient reports and medical records during the postoperative period.

    Time frame: From surgery until 48 hours postoperatively

  6. Length of Hospital Stay(days)

    Length of hospital stay is defined as the number of calendar days from the date of surgery (Day 0) until the date of hospital discharge , as recorded in the electronic medical record system

    Time frame: From the day of surgery (Day 0) to the date of hospital discharge (expected within 7-14 days postoperatively)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4. PubMed 38572751 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 11 months is below that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jul 2026 → Dec 2026 and completion Aug 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2025
First posted
Jan 20, 2026
StartActual
Jan 21, 2026
Primary completionEst.
Dec 25, 2026was Jul 2026
CompletionEst.
Jan 5, 2027was Aug 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Nov 4, 2026
Sites
The First Affiliated Hospital of Nanjing Medical University is now Recruiting
Nov 4, 2026
Primary completion
Jul 25, 2026→Dec 25, 2026
Nov 4, 2026
Study completion
Aug 5, 2026→Jan 5, 2027
Nov 4, 2026
Enrollment
147 (actual)→170 (estimated)
Nov 4, 2026
Contact
Study contact now listed: added x•••@njmu.edu.cn · •••1858; added h•••@163.com · •••8706. See the current contact
Nov 4, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The First Affiliated Hospital of Nanjing Medical University · Nanjing, ChinaContact added x•••@njmu.edu.cn · •••1858Contact added h•••@163.com · •••8706
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Completed→Recruiting
    The First Affiliated Hospital of Nanjing Medical University is now Recruiting
    Primary completion Jul 25, 2026→Dec 25, 2026
    Study completion Aug 5, 2026→Jan 5, 2027
    Enrollment 147 (actual)→170 (estimated)
    Contact Study contact now listed: added x•••@njmu.edu.cn · •••1858; added h•••@163.com · •••8706. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The First Affiliated Hospital of Nanjing Medical University · Nanjing, ChinaContact added x•••@njmu.edu.cn · •••1858Contact added h•••@163.com · •••8706
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07351474
Responsible party
Xiongxiong Pan (Associate Chief Physician, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Jan 20, 2026
Start date
Jan 21, 2026
Primary completion
Dec 25, 2026 (estimated)
Completion
Jan 5, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Xiongxiong Pan
Contact
xiongxiong@njmu.edu.cn
+86 13813801858
Siyang Li
Contact
hilary37727@163.com
+86 18745228706

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam

Start the discussion